Advertisement

Drugs & Aging

, Volume 35, Issue 8, pp 735–750 | Cite as

Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults

  • Alex Secora
  • G. Caleb Alexander
  • Shoshana H. Ballew
  • Josef Coresh
  • Morgan E. Grams
Original Research Article

Abstract

Background

Chronic kidney disease (CKD) afflicts many older adults and increases the risk for medication-related adverse events.

Objective

The aim of this study was to assess the prevalence and associated morbidity and mortality of polypharmacy (use of several medications concurrently), and potentially inappropriate medication (PIM) use in older adults, looking for differences by CKD status.

Methods

We quantified medication and PIM use (from Beers criteria, the Screening Tool of Older People’s Prescriptions, and Micromedex®) by level of estimated glomerular filtration rate (eGFR) for participants aged 65 years or older attending a baseline study visit in the Atherosclerosis Risk in Communities study (n =6392). We used zero-inflated negative binomial and Cox proportional hazards regressions to assess the relationship between baseline polypharmacy, PIM use, and subsequent hospitalization and death.

Results

Mean age at baseline was 76 (± 5) years, 59% were female, and 29% had CKD (eGFR < 60 ml/min/1.73 m2). Overall, participants reported 6.1 (± 3.5) medications and 2.3 (± 2.2) vitamins/supplements; 16% reported ≥ 10 medications; 31% reported a PIM based on their age. On average, participants with CKD reported more medications. A PIM based on kidney function was used by 36% of those with eGFR < 30 ml/min/1.73 m2. Over a median of 2.6 years, more concurrent medications were associated with higher risk of hospitalization and death, but PIM use was not. While those with CKD had higher absolute risks, there was no difference in the relative risks associated with greater numbers of medications by CKD status.

Conclusion

Polypharmacy and PIM use were common, with greater numbers of medications associated with higher risk of hospitalization and death; relative risks were similar for those with and without CKD.

Notes

Acknowledgements

Preliminary data from this study were presented in a spotlight poster session at the 33rd International Conference of Pharmacoepidemiology and Therapeutic Risk Management, Montreal, QC, Canada, 27–30 August 2017. The authors thank the staff and participants of the ARIC study for their important contributions

Author Contributions

Research idea and study design: AS, GCA, SHB, JC, MEG. Data analysis/interpretation: AS, GCA, SHB, JC, MEG. Statistical analysis: AS, MEG. Supervision or mentorship: GCA, JC, MEG. Each author contributed meaningfully to manuscript content during its preparation or revision, and accepts accountability for the overall work.

Compliance with Ethical Standards

Funding

Alex Secora, the principal author, is supported by grant T32 HL007024 from the NHLBI, National Institutes of Health; Morgan Grams is supported by grant K08DK092287 from the National Institute of Diabetes and Digestive and Kidney Diseases; and G. Caleb Alexander is supported by 1 U01 FD004977-02 from the US FDA. The ARIC study is performed as a collaborative investigation supported by contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C from the NHLBI. The funding sources had no role in the design and conduct of the study, analysis or interpretation of the data, and preparation or final approval of the manuscript prior to publication.

Conflict of interest

Dr. G. Caleb Alexander is Chair of the FDA’s Peripheral and Central Nervous System Advisory Committee, has served as a paid advisor to IQVIA, serves on the advisory board of MesaRx Innovations, is a member of OptumRx’s National P&T Committee, and holds equity in Monument Analytics, a healthcare consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. Alex Secora, G. Caleb Alexander, Shoshana H. Ballew, Josef Coresh and Morgan E. Grams declare that they have no conflicts of interest relevant to the content of this study.

Supplementary material

40266_2018_563_MOESM1_ESM.tiff (56 kb)
Supplementary material 1 (TIFF 55 kb)
40266_2018_563_MOESM2_ESM.tiff (66 kb)
Supplementary material 2 (TIFF 65 kb)
40266_2018_563_MOESM3_ESM.tiff (62 kb)
Supplementary material 3 (TIFF 61 kb)
40266_2018_563_MOESM4_ESM.docx (141 kb)
Supplementary material 4 (DOCX 141 kb)

References

  1. 1.
    He W, Goodkind D, Kowal P. An aging world: 2015, international population reports. Washington, DC: U.S. Government Publishing Office; 2016.Google Scholar
  2. 2.
    Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.CrossRefPubMedGoogle Scholar
  3. 3.
    Lassiter J, Bennett WM, Olyaei AJ. Drug dosing in elderly patients with chronic kidney disease. Clin Geriatr Med. 2013;29(3):657–705.CrossRefPubMedGoogle Scholar
  4. 4.
    Masoudi FA, Baillie CA, Wang Y, Bradford WD, Steiner JF, Havranek EP, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med. 2005;165(18):2069–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy. Drugs Aging. 2010;27(12):1019–28.CrossRefPubMedGoogle Scholar
  7. 7.
    Banerjee A, Mbamalu D, Ebrahimi S, Khan AA, Chan TF. The prevalence of polypharmacy in elderly attenders to an emergency department—a problem with a need for an effective solution. Int J Emerg Med. 2011;4(1):22.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rohrer JE, Garrison G, Oberhelman SA, Meunier MR. Epidemiology of polypharmacy among family medicine patients at hospital discharge. J Prim Care Commun Health. 2013;4(2):101–5.CrossRefGoogle Scholar
  9. 9.
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346–53.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012;105(8):437–45.CrossRefPubMedGoogle Scholar
  12. 12.
    Papaioannou A, Clarke JA, Campbell G, Bedard M. Assessment of adherence to renal dosing guidelines in long-term care facilities. J Am Geriatr Soc. 2000;48(11):1470–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Chang F, O’Hare AM, Miao Y, Steinman MA. Use of renally inappropriate medications in older veterans: a national study. J Am Geriatr Soc. 2015;63(11):2290–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Schottker B, Saum KU, Muhlack DC, Hoppe LK, Holleczek B, Brenner H. Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol. 2017;73(8):1041–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Flaherty JH, Perry HM, Lynchard GS, Morley JE. Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci. 2000;55(10):554.CrossRefGoogle Scholar
  18. 18.
    Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002;50(12):1962–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Hellden A, Bergman U, von Euler M, Hentschke M, Odar-Cederlof I, Ohlen G. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study. Drugs Aging. 2009;26(7):595–606.CrossRefPubMedGoogle Scholar
  20. 20.
    Leendertse AJ, van Dijk EA, De Smet PA, Egberts TC, van den Bemt PM. Contribution of renal impairment to potentially preventable medication-related hospital admissions. Ann Pharmacother. 2012;46(5):625–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE Study. J Gerontol A Biol Sci Med Sci. 2006;61(2):170–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Rich MW. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev. 2012;17(4–5):589–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Muhlack DC, Hoppe LK, Weberpals J, Brenner H, Schottker B. The association of potentially inappropriate medication at older age with cardiovascular events and overall mortality: a systematic review and meta-analysis of cohort studies. J Am Med Dir Assoc. 2017;18(3):211–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Doogue MP, Polasek TM. Drug dosing in renal disease. Clin Biochem Rev. 2011;32(2):69–73.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hassan Y, Al-Ramahi R, Abd Aziz N, Ghazali R. Drug use and dosing in chronic kidney disease. Ann Acad Med Singap. 2009;38(12):1095–103.PubMedGoogle Scholar
  27. 27.
    Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–73.CrossRefPubMedGoogle Scholar
  28. 28.
    Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107(37):6.Google Scholar
  29. 29.
    Via-Sosa MA, Lopes N, March M. Effectiveness of a drug dosing service provided by community pharmacists in polymedicated elderly patients with renal impairment–a comparative study. BMC Fam Pract. 2013;14:96.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Hanlon JT, Wang X, Handler SM, Weisbord S, Pugh MJ, Semla T, et al. Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients. J Am Med Dir Assoc. 2011;12(5):377–83.CrossRefPubMedGoogle Scholar
  31. 31.
    Nielsen AL, Henriksen DP, Marinakis C, Hellebek A, Birn H, Nybo M, et al. Drug dosing in patients with renal insufficiency in a hospital setting using electronic prescribing and automated reporting of estimated glomerular filtration rate. Basic Clin Pharmacol Toxicol. 2014;114(5):407–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med. 2001;16(6):369–75.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286(22):2839–44.CrossRefPubMedGoogle Scholar
  34. 34.
    van Dijk EA, Drabbe NR, Kruijtbosch M, De Smet PA. Drug dosage adjustments according to renal function at hospital discharge. Ann Pharmacother. 2006;40(7–8):1254–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function–an underestimated problem? Nephrol Dial Transplant. 2006;21(11):3164–71.CrossRefPubMedGoogle Scholar
  36. 36.
    Parker K, Aasebo W, Stavem K. Potentially inappropriate medications in elderly haemodialysis patients using the STOPP criteria. Drugs Real World Outcomes. 2016;3(3):359–63.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sheen SS, Choi JE, Park RW, Kim EY, Lee YH, Kang UG. Overdose rate of drugs requiring renal dose adjustment: data analysis of 4 years prescriptions at a tertiary teaching hospital. J Gen Intern Med. 2008;23(4):423–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Khanal A, Castelino RL, Peterson GM, Jose MD. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J. 2014;44(1):77–85.CrossRefPubMedGoogle Scholar
  39. 39.
    Hanlon JT, Aspinall SL, Semla TP, Weisbord SD, Fried LF, Good CB, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc. 2009;57(2):335–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Richardson MM, Nolin TD. A decade after the KDOQI CKD guidelines: impact on medication safety. Am J Kidney Dis. 2012;60(5):713–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ. 2005;331(7511):263.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Inter Suppl. 2012;2:337–414.CrossRefGoogle Scholar
  43. 43.
    Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging. 2005;22(1):69–82.CrossRefPubMedGoogle Scholar
  44. 44.
    Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165(1):68–74.CrossRefPubMedGoogle Scholar
  45. 45.
    Dedhiya SD, Hancock E, Craig BA, Doebbeling CC, Thomas J. Incident use and outcomes associated with potentially inappropriate medication use in older adults. Am J Geriatr Pharmacother. 2010;8(6):562–70.CrossRefPubMedGoogle Scholar
  46. 46.
    Lu WH, Wen YW, Chen LK, Hsiao FY. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ. 2015;187(4):130.CrossRefGoogle Scholar
  47. 47.
    Skoldunger A, Fastbom J, Wimo A, Fratiglioni L, Johnell K. Impact of inappropriate drug use on hospitalizations, mortality, and costs in older persons and persons with dementia: findings from the SNAC study. Drugs Aging. 2015;32(8):671–8.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Pozzi C, Lapi F, Mazzaglia G, Inzitari M, Boncinelli M, Geppetti P, et al. Is suboptimal prescribing a risk factor for poor health outcomes in community-dwelling elders? The ICARe Dicomano study. Pharmacoepidemiol Drug Saf. 2010;19(9):954–60.CrossRefPubMedGoogle Scholar
  49. 49.
    Barnett K, McCowan C, Evans JM, Gillespie ND, Davey PG, Fahey T. Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community. BMJ Qual Saf. 2011;20(3):275–81.CrossRefPubMedGoogle Scholar
  50. 50.
    Beer C, Hyde Z, Almeida OP, Norman P, Hankey GJ, Yeap BB, et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study. Br J Clin Pharmacol. 2011;71(4):592–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Lin HY, Liao CC, Cheng SH, Wang PC, Hsueh YS. Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases: experience in a Taiwanese medical setting. Drugs Aging. 2008;25(1):49–59.CrossRefPubMedGoogle Scholar
  52. 52.
    The Atherosclerosis Risk in Communities (ARIC). Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687–702.CrossRefGoogle Scholar
  53. 53.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3:1–150.CrossRefGoogle Scholar
  54. 54.
    Ballew SH, Chen Y, Daya NR, Godino JG, Windham BG, McAdams-DeMarco M, et al. Frailty, Kidney Function, and Polypharmacy: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2017;69(2):228–36.CrossRefPubMedGoogle Scholar
  55. 55.
    Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Fick DM, Semla TP, Beizer J, Brandt N, Dombrowski R, DuBeau CE, et al. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  58. 58.
    O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis. 2009;54(1):33–42.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Okparavero AA, Tighiouart H, Krishnasami Z, Wyatt CM, Graham H, Hellinger J, et al. Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. Antivir Ther. 2013;18(6):793–802.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Sharif-Askari FS, Syed Sulaiman SA, Saheb Sharif-Askari N, Hussain AAS. Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. PLoS One. 2014;9(4):e95991.CrossRefPubMedGoogle Scholar
  62. 62.
    Hug BL, Witkowski DJ, Sox CM, Keohane CA, Seger DL, Yoon C, et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney. Kidney Int. 2009;76(11):1192–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):32.CrossRefGoogle Scholar
  64. 64.
    Zhang L, Xu N, Xiao S, Arya V, Zhao P, Lesko LJ, et al. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharm. 2012;52(Suppl 1):90S.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Welch Center for Prevention, Epidemiology and Clinical ResearchJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  3. 3.Center for Drug Safety and EffectivenessJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  4. 4.Division of General Internal Medicine, Department of MedicineJohns Hopkins MedicineBaltimoreUSA
  5. 5.Division of Nephrology, Department of MedicineJohns Hopkins MedicineBaltimoreUSA

Personalised recommendations